Afleveringen
-
Guest: Ibrahim Hussain, M.D.
Neurological spine surgeon Dr. Ibrahim Hussain explains how expandable cages are being used in minimally invasive transforaminal lumbar interbody fusions to optimize patient outcomes. These cages can be inserted with a very low profile to restore height and lordosis, and enable a faster recovery.
At Och Spine at NewYork-Presbyterian, surgeons are pursuing innovative solutions to provide a better quality of life for patients with degenerative disc disease and other spine conditions.
© 2026 NewYork-Presbyterian
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sarah Sammons, MD
Despite advances in the treatment of HR-positive HER2-negative advanced breast cancer, patients with PIK3CA-mutated disease who progress after a CDK4/6 inhibitor still face limited effective and tolerable treatment options.1 This unmet need has fueled interest in zovegalisib (formerly RLY-2608), a next generation, pan-mutant-selective PI3Kα inhibitor designed to spare wild-type protein and potentially reduce class-related toxicities.2 Dr. Sarah Sammons joins Dr. Charles Turck to review key findings from the first-in-human ReDiscover trial of zovegalisib + fulvestrant that supported initiation of the Phase 3 ReDiscover-2 study3,4, which is currently enrolling. They also discuss ReDiscover-2 eligibility criteria, along with patient selection and screening considerations, using hypothetical case scenarios. Dr. Sammons is the Associate Director of the Metastatic Breast Cancer Program at the Dana-Farber Cancer Institute in Boston, Massachusetts.
References:
Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7)doi:10.3390/ijms22073464 Varkaris A, Pazolli E, Gunaydin H, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples antitumor activity from hyperinsulinemia. Cancer Discovery. 2024;14(2):240–257. doi:10.1158/2159-8290.cd-23-0944 ClinicalTrials.gov. NCT06982521. Accessed April 12, 2026. https://clinicaltrials.gov/study/NCT06982521 Rugo HS, Saura C, Jhaveri K, et al. Poster PS5-08-25: … -
Zijn er afleveringen die ontbreken?
-
Guest: Mirella Mourad, M.D.
On this episode of Advances in Care, host Erin Welsh is joined by Dr. Mirella Mourad, maternal-fetal medicine specialist at NewYork-Presbyterian and co-director of the Preterm Birth Prevention Center at Columbia, to explore a groundbreaking new technology aimed at improving the diagnosis and treatment of preterm birth.
Preterm birth impacts approximately 1 in 10 pregnancies in the United States, making it a leading cause of neonatal complications and long-term health challenges. But despite its prevalence and associated risks, innovative solutions to address the condition have lagged behind. To address this gap, Dr. Mourad and her collaborator, Dr. Kristin Meyers, a professor of mechanical engineering at Columbia’s School of Engineering, are developing a new tool: a patient-specific “digital twin” of the cervix. This advanced technology has the potential to revolutionize obstetric care for patients by allowing clinicians to test new treatment methods, collect data to better understand why certain people are at risk for preterm birth, and overall, catalyze innovation in the historically under-researched field of maternal-fetal medicine, ultimately helping to drive better outcomes and successful pregnancies. Dr. Mourad also discusses how this digital twin can potentially assist with identifying women with placenta accreta spectrum disorder and inform more precise and …
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Maggie Emerson, DNP, APRN, PMHNP-BC
Guiding patients and caregivers through the fast-moving landscape of digital therapeutics can be a challenging but worthwhile part of providing effective and accessible care. That’s why Dr. Charles Turck speaks with Dr. Maggie Emerson about how we can best partner with patients and caregivers around this relatively new treatment in mental health care. Dr. Emerson is a Clinical Associate Professor at the University of Nebraska Medical Center College of Nursing in Omaha.
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Joseph Goldberg, MD
Our understanding of depression has evolved over the past several decades, leading us to some potential new treatment options that focus on neuroplasticity, chemical imbalance, and negative cognitive biases. Learn more about the history of depression treatment approaches and the emerging concept of neuroplasticity with Dr. Charles Turck and Dr. Joseph Goldberg, Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City.
-
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Madhukar H. Trivedi, MD
The brain is constantly changing as a result of experience, stress, emotional processing, learning, and memory.1 And neuroplasticity adds another layer to these approaches by focusing on what’s actually changing in the brain.2 Tune in with Dr. Charles Turck as he speaks with Dr. Madhukar Trivedi, Founding Director of the Center for Depression Research and Clinical Care and Chief of the Division of Mood Disorders at the University of Texas Southwestern Medical Center in Dallas, Texas.
References:
Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63-77. Mateos-Aparicio P, Rodriguez-Moreno A. The impact of studying brain plasticity. Front Cell Neurosci. 2019;13:66. -
Guest: Thomas S. Bottiglieri, D.O.
On this episode of Advances in Care, host Erin Welsh sits down with Dr. Thomas Bottiglieri, Chief of the Primary Care Sports Medicine Division at NewYork-Presbyterian and Columbia, to discuss the evolving landscape of concussion care—from prevalence to emerging diagnostic breakthroughs.
With over 2 million estimated concussions occurring annually in the United States and many of them affecting young athletes, Dr. Bottiglieri and his colleagues have sought to develop a more accurate and accessible way to objectively diagnose concussion. While a single injury may not cause long-term issues, research shows that repeated head trauma—and lack of proper care—can lead to premature neurodegeneration.
During their research to improve diagnostic measures, Dr. Bottiglieri and his team discovered a biomarker associated with severe concussions: a subtle tremor of the head and neck that becomes amplified when a concussed patient tries to visually focus on a target.
This discovery led to the development of ProScope, an innovative eye-tracking software tool that measures head and neck stability and can detect the diagnostic biomarker with over 80% sensitivity. With the advent of these tools, clinicians can now, for the first time, objectively measure concussion. A former competitive athlete himself, Dr. Bottiglieri hopes that the ProScope tool …
-
Guest: Pierre Elias, M.D.
Learn how Dr. Pierre Elias and his team at NewYork-Presbyterian and Columbia have established a deep learning lab called CRADLE, which uses basic medical imaging, EKGs, and echocardiograms to build advanced AI models that help identify all forms of structural heart disease, including cardiac amyloidosis and valvular regurgitation. These tools not only improve screening access but enable early detection.
© 2026 NewYork-Presbyterian
-
Host: Jennifer Caudle, DO, FACOFP
Guest: Felicia Cosman, MD
Starting with the presence of a prior fracture, advancing age, and bone mineral density, there are numerous factors that increase the risk of fracture in postmenopausal women.1 But despite these common predictors, treatment rates of osteoporosis in postmenopausal women have consistently remained low.2 For instance, in the last decade, less than 10% of women aged 50 years and older have received treatment for their osteoporosis.2 To help address these unmet needs, Dr. Jennifer Caudle speaks with Dr. Felicia Cosman about best practices for diagnosing and treating postmenopausal osteoporosis patients who are at a very high risk of fracture. Dr. Cosman is a Professor of Medicine Emerita at Columbia University Vagelos College of Physicians and Surgeons in New York.
References:
Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. JAMA. 2002;288:1889-1897. Data on file, Amgen; 2024. -
Guest: Courtney Crawford, MD, FACS
Guest: Raj Maturi, MD
While anti-VEGF therapy can deliver vision gains with consistent, frequent injections in clinical trials, it may be challenging to sustain this in real-world practice.1 Ocular gene therapy could be a potential option for patients with neovascular age-related macular degeneration if approved. With this approach, transgenes are delivered to the eye by adeno-associated viruses (AAVs).2-4 Learn more with Drs. Courtney Crawford and Raj Maturi, who shared their perspectives on investigational gene therapy, patient conversations, and surgical considerations at the 2025 American Academy of Ophthalmology annual meeting in Orlando, Florida.
Dr. Crawford is a board-certified retina specialist and founder of Star Retina in Burleson, Texas. He previously served for 10 years as a physician in the U.S. Army, where he attained the rank of Lieutenant Colonel. Dr. Maturi is a board-certified retina specialist at the Midwest Eye Institute and founder of Retina Partners Midwest in Carmel, Indiana, where he focuses on macular, retina, and vitreous care.
References:
Weng CY, Singh RP, Gillies MC, Regillo CD. Optimizing visual outcomes in patients with neovascular age-related macular degeneration: the potential value of sustained anti-VEGF therapy. Ophthalmic Surg Lasers Imaging Retina. 2023;54:654–659. Petrich J, Marchese D, Jenkins C, Storey M, Blind J. … -
Host: Yuval Zabar, MD
Guest: Michelle Mielke, PhD
Guest: Henrik Zetterberg, MD, PhD
For the latest insights on tau and neurodegeneration biomarkers in Alzheimer’s disease (AD), tune in to this recorded presentation featuring Doctor Michelle Mielke and Professor Henrik Zetterberg. Together, they delve into the role of tau in AD, exploring the ‘tau cascade’, the current use of tau and neurodegeneration biomarkers in tracking disease progression, and how the AD biomarker landscape may evolve over time. Doctor Mielke is a Professor of Epidemiology and Neurology at the Wake Forest University School of Medicine, and Professor Zetterberg is a Professor of Neurochemistry at the University of Gothenburg.
To learn more about tau in Alzheimer’s disease, explore the Know Tau medical education platform. Know Tau is created and funded by Biogen and is intended for healthcare professionals only.
-
Guest: Lauren Osborne, M.D.
Lauren Osborne, M.D., a reproductive psychiatrist at NewYork-Presbyterian and Weill Cornell Medicine and vice chair for clinical research for the Department of Obstetrics and Gynecology, discusses her research into the biological basis of postpartum depression. In a recent study, Dr. Osborne and her team were the first to analyze the entire metabolic pathway of progesterone, measuring both positive and negative allosteric modulators of the GABAA receptor throughout pregnancy and ultimately identifying a potential biomarker to predict risk. They are continuing to study and build upon these findings, with the goal of enabling better prediction and treatment options to address, or even prevent, postpartum depression.
© 2026 NewYork-Presbyterian
-
Host: Holly M. Brothers, PhD
Guest: Niklas Mattsson-Carlgren, MD, PhD
The prevalence of dementia is projected to almost double every 20 years.1 Alzheimer’s disease (AD) is the most common cause of dementia,2 making early diagnosis and management increasingly important. Based on our current understanding of its pathology, AD is an amyloid driven tauopathy3 with biomarker changes occurring years before clinical symptoms appear.4 Learn more with this webinar featuring Dr Niklas Mattsson-Carlgren, Associate Professor at Lund University as he explores the relationship between amyloid beta and tau, the correlation between pathology and clinical symptoms, and biomarker progression across the AD continuum.
To learn more about tau in Alzheimer’s disease, explore the Know Tau medical education platform. Know Tau is created and funded by Biogen and is intended for healthcare professionals only.
References:
Alzheimer’s Disease International. Numbers of people with dementia worldwide. Available from: https://www.alzint.org/resource/numbers-of-people-with-dementia-worldwide/ (Accessed June 2025) Alzheimer’s Association. Alzheimer’s disease facts and figures. Available from: https://www.alz.org/alzheimers-dementia/facts-figures (Accessed June 2025) Aksman LM, et al. Brain 2023;146:4935–4948 Jack CR Jr, et al. Alzheimers Dement 2018;14:535–562 -
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kormal Jhaveri, MD, FACP
Guest: Vanessa Soto-Romano, RN
There’s been recent progress with antibody-drug conjugates (ADCs) for HER2-negative breast cancers,1-3 and most recently, patients with metastatic HR+ HER2- breast cancer. The phase III TROPION-Breast01 study examined the efficacy and safety of datopotamab deruxtecan-dInk (Dato-DXd) compared to investigator’s choice single-agent chemotherapy, resulting in the approval of this agent in January 2025. Joining Dr. Charles Turck to discuss Dato-DXd for patients with HR-positive, HER2-negative metastatic breast cancer, data from the TROPION-Breast01 trial, and strategies for managing select adverse reactions with this therapy are Dr. Komal Jhaveri and Nurse Vanessa Soto-Romano. Dr. Jhaveri is a breast medical oncologist and early drug development specialist at Memorial Sloan Kettering Cancer Center in New York, and Nurse Soto-Romano is a Clinical Trials Nurse, also at Memorial Sloan Kettering Cancer Center in New York.
Dr. Komal Jhaveri
Consultant/advisory board role: Novartis, Pfizer, Genentech, Eisai, AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Menarini/Stemline, Gilead, Scorpion Therapeutics, Bicycle Therapeutics, Olema Pharmaceuticals, Lilly/Loxo Oncology, Merck Pharmaceuticals, Zymeworks, Halda Therapeutics, Arivinas and Rayzebio
Research Funding support to the Institution: Novartis, Genentech, AstraZeneca, Pfizer, Lilly/Loxo Oncology, Zymeworks, Gilead, PUMA Biotechnology, Merck Pharmaceuticals, Scorpion Therapeutics, Rayzebio, Eisai, Bicycle Therapeutics, Bridge Bio Oncology Therapeutics, and Blueprint Medicines.Nurse Soto-Romano
Consultant/advisory board role: AstraZeneca … -
Host: Jennifer Caudle, DO
Guest: Wendy Wright, DNP, FNP-BC, ANP-BC
Randomized controlled trials have shown data supporting the safety and efficacy of cell-based influenza vaccines in adults and children.1-4 However, effectiveness studies have historically relied on outcomes based on clinical diagnosis of influenza-like illness rather than test-confirmed influenza.5 Test-confirmed influenza outcomes provide a more specific evaluation of influenza vaccine effectiveness and can help reveal the clinical differences between cell-based versus egg-based vaccines.6 A retrospective test-negative real-world study including more than 106,000 patients compared the cell-based vaccine with egg-based vaccines.7 Dr. Jennifer Caudle sits down with Dr. Wendy Wright to review the key findings from this analysis and their implications. Dr. Wright is a board-certified adult and family nurse practitioner based out of Amherst, New Hampshire as well as the owner of Wright and Associates Family Healthcare.
References:
FLUCELVAX. Package insert. Seqirus Inc. Bart S, Cannon K, Herrington D, et al. Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: a phase III, double-blind, multicenter, randomized, non-inferiority study. Hum Vaccin Immunother. 2016;12(9):2278–88. doi:10.1080/21645515.2016.1182270. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, et al. Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis. 2010;51(9):997–1004. doi:10.1086/656578. Diez-Domingo J, de Martino M, Lopez … -
Guest: Brian Gill, M.D.
Brian Gill, M.D., a neurosurgeon at NewYork-Presbyterian and Columbia, talks about a new clinical trial evaluating a device that can temporarily open the blood-brain barrier (BBB) to more effectively treat glioblastoma. Dr. Gill explains how this new sonication device uses focused ultrasound to temporarily disrupt the BBB in order to administer chemotherapy directly into the tumor bed. The trial is building on promising results from phase 1 and phase 2 trials, which demonstrated safety, efficacy, and the potential to enhance quality of life for patients with recurrent glioblastoma.
© 2025 NewYork-Presbyterian
-
Guest: Joel Gabre, M.D, MPH
On this episode of Advances in Care, host Erin Welsh and Dr. Joel Gabre, a gastroenterologist at NewYork-Presbyterian and Columbia who specializes in cancer care, discuss the ongoing rise in colorectal cancer rates among younger individuals. Dr. Gabre lays out trends observed by the medical community in colorectal cancer rates, including the increasing likelihood by birth cohort for patients to develop this disease. He also talks about the main differences in colorectal cancer for patients from these different cohorts, most notably the location where cancers are likely to develop in the colon.
In addition, Dr. Gabre shares some of the leading hypotheses for why colon cancer rates are rising in younger people, and how clinicians and researchers are focused on searching for answers to improve prevention and treatment options. He gets into the importance of the western diet in developing these forms of cancer and shares details about his team’s recent findings regarding changes at the cellular level that could be contributing to the accelerated growth of these cancers.
Finally, Dr. Gabre speaks to his personal experiences as a gastroenterologist who has seen first-hand the rise in colon cancer rates among his younger patients. He shares a story of what …
-
Guest: David Majure, M.D., MPH
On this episode of Advances in Care, host Erin Welsh talks to Dr. David Majure, a cardiologist and heart failure specialist at NewYork-Presbyterian and Weill Cornell Medicine. Together, they discuss the rapid rise in GLP-1 research over the past few years, indicating new applications for these therapies to help a wide variety of patients. They explore how GLP-1s work on a molecular level and how using them to treat diabetes revealed other potential cardiovascular benefits.
Dr. Majure highlights several recent studies that explore the effects of semaglutide and tirzepatide on patients with heart failure, particularly those with preserved ejection fraction. This new research demonstrates that GLP-1s can be an effective treatment beyond diabetes, helping with weight management and cardiovascular disease. Dr. Majure breaks down what effects doctors can expect to see in patients who are prescribed GLP-1s, including the difference in outcomes between semaglutide and tirzepatide. He also notes the potential risk factors, cautioning that while these medications are effective, the focus in addressing heart disease should always remain on prevention.
© 2025 NewYork-Presbyterian
-
Guest: Juan P. Rocca, M.D., MHA
On this episode of Advances in Care, host Erin Welsh hears from Dr. Juan P. Rocca, a transplant surgeon at NewYork-Presbyterian and Weill Cornell Medicine who recently led the first fully robotic liver transplant in New York.
Dr. Rocca details the recent developments in robotic surgery at Weill Cornell Medicine’s Division of Liver Transplantation and Hepatobiliary Surgery, including an ongoing push to advance from laparoscopic and open surgical methods, and now to robotics. He explains why the robotic approach is optimal for complex liver surgeries and discusses how he and his team have been training to make robotic living donor hepatectomies a standard in their department.
Then, Dr. Rocca breaks down the process of the liver transplant operation that became the first fully robotic execution in New York. He describes the most critical steps of the procedure, how it felt to achieve this milestone, and the example that he hopes to set for other institutions beyond NewYork-Presbyterian and Weill Cornell Medicine.
© 2025 NewYork-Presbyterian
-
Immune imprinting refers to how the immune system's first encounter with a virus, such as influenza, leaves a lasting imprint that shapes future immune responses.1,2 However, influenza vaccines may affect this process—particularly when egg-based ones are used. Tune in to learn about the impact of immune imprinting, the role that vaccines play in this process, and how switching to non-egg-based vaccines could help redirect immune responses and possibly create more effective defenses in people of all ages.3,4
References:
King SM, Bryan SP, Hilchey SP, Wang J, Zand MS. First impressions matter: Immune imprinting and antibody cross-reactivity in influenza and SARS-CoV-2. Pathogens. 2023;12(2):169. doi:10.3390/pathogens12020169 Zhang A, Stacey HD, Mullarkey CE, Miller MS. Original antigenic sin: How first exposure shapes lifelong anti-influenza virus immune responses. J Immunol. 2019;202(2):335–340. doi:10.4049/jimmunol.1801149 Rockman S, Laurie K, Ong C, et al. Cell-based manufacturing technology increases antigenic match of influenza vaccine and results in improved effectiveness. Vaccines (Basel). 2022;11(1):52. doi:10.3390/vaccines11010052 Liu F, Gross FL, Jefferson SN, et al. Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination. J Clin Invest. 2021;131(8):e146138. doi:10.1172/JCI146138USA-CRP-24-0038 July 2025
- Laat meer zien
